Biotechnology

Enquiry IconContact Us

The biotech industry includes bio-pharma, bio-services, bio-agri, bio-industrials and bioinformatics. Biopharma is a rapidly growing segment that accounts for a dominant share in this sector. Advancements in biotechnology have enabled researchers to evaluate and identify target biomarkers/cell receptors to develop targeted and personalized therapies. Scientific research and technological advancements have resulted in the emergence of various personalized medicines that are undergoing research. According to research conducted by the Personalized Medicine Coalition, 42% of all compounds and 73% of oncology compounds in the pipeline possess the potential to be personalized medicine. Moreover, according to this study, it is expected that companies will increase their investment in R&D of personalized medicines by 1/3rd over the following five years. The study found that over 20% of drugs approved in 2014 were personalized medicines.

The biotechnology sector has witnessed some disruptive innovations such as gene and cell therapies, immunotherapy, and antibody drug conjugates. Advancement in stem cell therapy is resulting in effective treatment therapies for chronic conditions, organ growth and repair and disease prevention.

Key Challenges

Biotech products have extensive application in oncology and autoimmune disease treatment. However, the cost of these drugs is high owing to extensive research and trials that need to be carried out for the same. Therefore, there is constant pressure to reduce price and increase accessibility, especially in emerging economies. In the U.S., companies are facing reimbursement issues with respect to biopharmaceutical products. Besides, there are regulatory and scientific challenges faced by the sector. Scientific research for new molecules and targeted therapies is capital intensive and challenging owing to growing concern for safety of the drug.

Also, there is lack of awareness about personalized medicine among most healthcare providers, which may hamper its adoption. Clinical adoption of biotechnology products is essential for its success. However, it significant scientific evidence and backing is required to ensure its safety.

“Translating genomic discoveries into personalized medicines entails overcoming substantial scientific, regulatory, and economic challenges, including identifying validated biomarkers, as well as developing personalized therapeutics and clinically relevant diagnostic tests.”

  • Tufts Center for the Study of Drug Development

Opportunities

The biopharmaceutical sector offers vast lucrative growth opportunities. High efficacy and safety of biopharmaceutical products has led to a growth in their demand, Furthermore, consumers are willing to pay high prices for biopharmaceutical products compared to other conventional products. Biopharmaceutical brands have set new standards for blockbuster drugs by recording an annual average sale of over US$ 2bn. Drugs such as Humira have generated sales revenue of over US$ 10bn.

Governments in emerging economies are endorsing biosimilars as cost-effective alternatives to biotech products, which is expected to create significant growth opportunities for manufacturers of generic drugs. Therefore, cost-effectiveness and high quality are prime parameters that need to be considered while developing biosimilars. Recent and upcoming biologic patent expirations include the following:

  • Erbitux (cetuximab) - February 2016
  • Rituxan (rituximab) - September 2016
  • Herceptin (trastuzumab) - June 2019
  • Avastin (bevacizumab) - July 2019
  • Aranesp (darbepoetin alfa) - May 2024
  • Enbrel (etanercept) - November 2028

Companies such as Teva Pharmaceuticals, Hospira, Sandoz, and Amgen are focusing on development of biosimilars and vaccines as preventive measures in addition to treatment. For instance, in 2015, Zarxio TM became the first biosimilar to be approved in the U.S. market. The EMA approved Mosquirix, a malaria vaccine, in the same year. Extensive research is currently underway to develop a dengue vaccine, which could be another breakthrough pharmaceutical product in the near future.

Conclusion

The increasing research in the biotechnology sector is expected to result in higher number of biopharmaceutical products seeking FDA approvals. Biopharmaceuticals are positioned to be promising treatment solutions that would improve patient outcomes and help with reduction of the cost of drug development.

View More

Biotechnology Published Insights

Coherent Market Insights

Clostridium Vaccine Market, by Vaccine (PF-06425090 and VLA84) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Pipeline Analysis, 2022-2028

Published Date : Mar 2023

Clostridium difficile infections are the most widely recognized cause of hospital acquired infectious diarrhea. There is a critical need for development of prevention vaccine for this disease. Clostridium difficile, is a gram-positive bacterium, whic... View more

Coherent Market Insights

Pneumococcal Vaccines Market, by Vaccine Type (PCV10, PCV13, and PPSV23), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published Date : Aug 2022

Pneumococcal vaccine is used to prevent infection caused by streptococcus pneumoniae bacteria. There are two types of pneumococcal vaccines: pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. The Centers for Di... View more

Coherent Market Insights

Nerve Biologic Products Market, by Product Type (Nerve Wraps, Nerve Grafts, Nerve Conduit, and Nerve Capping), by Application (Nerve Grafting, Direct Nerve Repair / Neurorrhaphy, Dural Defects, and Peripheral Nerve Injuries), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Published Date : Mar 2023

Nerve biologic products include artificial nerve conduit, nerve graft, nerve wraps, or nerve capping devices used for guiding axonal regrowth to facilitate nerve regeneration. These devices are majorly used in clinical treatments for nerve injuries. Nerve biologic pro... View more

Coherent Market Insights

Recombinant Human Endostatin Market, by Application (Medical Application, Scientific Application), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Published Date : Mar 2023

Endostatin is a protein located in most Basement Membranes (BMs) in the body such as vascular basement membranes. A number of clinical studies have validated the significant survival benefits of recombinant human endostatin in treating late stage Non-Small-Cell Lung C... View more

Coherent Market Insights

Tissue engineering Market, by Material Type (Synthetic, Biological, and Others), by Application (Dermal, Orthopedic, Dental, Neurology, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published Date : Aug 2022

Tissue engineering is an interdisciplinary field addressed to develop functional three-dimensional tissues combining cells, scaffolds, and bioactive molecules. This field involves scientific areas such as cell biology, chemistry, material science, molecular biology, m... View more

Coherent Market Insights

Monoclonal Antibody Diagnostic Reagents Market, by Diagnostic Tests (Dot-immunogold Filtration Assay, Double Antigen Sandwich Chemiluminescence Method, Enzyme Linked Immunosorbent Assay, and Recombinant Immunoblot Assay), by Application (Hormones Diagnosis, Tumor Monitoring, Virus Detection, and Others) and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Published Date : Mar 2023

Antibodies are common and essential research tools for various applications, including enzyme-linked immunosorbant assay (ELISA), flow cytometric analysis, immunoprecipitation, immunocytochemistry, immunohistochemistry, and western blotting. Monoclonal antibodies (MAb... View more

Coherent Market Insights

Non-Insulin Therapies for Diabetes Market, by Drug Class (Biguanides, Sulfonylureas Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, GLP-1 Analogs, and Sodium-glucose co-transporter-2 (SGLT2) inhibitors), by Route of Administration (Oral and Injectable), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Published Date : Mar 2023

Non-insulin therapies are mostly used in type 2 diabetes patients, where body either does not produce enough insulin or is unable to effectively use the insulin it produces. Non-insulin-based medication works with different mechanism of action to reduce blood glucose ... View more

Coherent Market Insights

Plant-based Vaccines Market, by Vaccine Type (Bacterial Vaccines, Viral Vaccines, Parasite Vaccines, and Others), by Source (Tobacco Plant, Maize, Potato, and Others),  by Application (Influenza, Covid-19, Zika Virus, Ebola Virus, Poultry Disease, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published Date : May 2021

Plant serves as an important source to produce cost-effective vaccine derivatives. Plant-based production of vaccine helps to reduce economic burden of infectious disease in emerging economies, owing to its large-scale production and cost-efficiency. Various clinical ... View more

Coherent Market Insights

Monovaccine (Epstein - Barr virus) Market by Application (Mononucleosis, Endemic Burkitt’s lymphoma, Hodgkin’s lymphoma, Gastric carcinomas, Multiple sclerosis, and Nasopharyngeal Carcinoma) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Published Date : May 2019

Mononucleosis also known as mono or kissing disease is an infectious illness caused by Epstein-Barr virus. This virus is generally spread through saliva hence, commonly called as kissing disease. It can also be spread through other ways such as sharing drinks or utens... View more

Subscribe Newsletter

Kindly subscribe for our latest news & articles.